SCHEMBL15840555

SCHEMBL15840555

COc1ccc(CC(=O)NC(=S)Nc2ccc(S(=O)(=O)NCCc3ccccc3)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.71
ALDH1A1 P00352 6/20 0.68
CYP3A4 P08684 1/20 0.68
CYP2C9 P11712 1/20 0.68
CYP2C19 P33261 1/20 0.68
KMT2A Q03164 3/20 0.67
PPARG P37231 2/20 0.64
POLB P06746 1/20 0.64
LMNA P02545 3/20 0.63
MEN1 O00255 2/20 0.60
HTT P42858 1/20 0.60
GPR55 Q9Y2T6 2/20 0.60
SGMS1 Q86VZ5 4/20 0.59
ALOX12 P18054 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
MAPT P10636 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27496854 0.85 PPARG (0.83) ALDH1A1KMT2APPARGPOLBLMNA
SCHEMBL14096626 0.84 RAB9A (1.00) RAB9AALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL15840617 0.82 GPR55 (0.66) ALDH1A1KMT2APPARGLMNAMEN1
SCHEMBL15840624 0.81 ALDH1A1 (1.00) RAB9AALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL15840505 0.81 GPR55 (0.65) RAB9AALDH1A1KMT2APPARGPOLB
SCHEMBL7109149 0.80 ALDH1A1 (1.00) ALDH1A1POLBSGMS1SMN1; SMN2
SCHEMBL11113173 0.79 ALDH1A1 (0.79) ALDH1A1KMT2APPARGPOLBLMNA
SCHEMBL25132370 0.79 ALDH1A1 (0.71) ALDH1A1KMT2APPARGLMNAMEN1
SCHEMBL15840638 0.79 ALDH1A1 (0.68) ALDH1A1KMT2APPARGPOLBLMNA
SCHEMBL15840535 0.79 GPR55 (0.67) RAB9AALDH1A1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed
CN-102994611-A Establishing method for drug screening model of high-throughput Japanese encephalitis virus helicase inhibitor UNIV HUAZHONG AGRICULTURAL 2013-03-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 RAB9A 2629/4885ALDH1A1 4348/4885CYP3A4 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.